Evonik announced that it is selling selected production assets for pharmaceutical ingredients in Hanau, Germany, to the contract manufacturer ProChem Group.
The transaction is expected to close on June 19, 2026. Evonik said the asset sale supports the growth strategy of its Health Care business by streamlining its asset footprint and sharpening its focus on core growth areas.
Evonik Health Care is focusing its investment on advanced oral and injectable drug delivery technologies, precision biosolutions such as lipids for mRNA and gene delivery, and advanced cell-culture ingredients.
By acquiring the Hanau facilities, ProChem Group is expected to strengthen its production capabilities, enhance its technological expertise, and expand services for pharmaceutical customers.
Evonik’s Hanau site has supported the pharmaceutical industry with APIs, intermediates, and pharmaceutical lipids. As part of its Health Care growth strategy, Evonik discontinued keto acid production in Hanau at the end of 2025.
Evonik said its pharmaceutical-grade keto and amino acids portfolio has been consolidated under the REXIM brand at its sites in Wuming, China, and Ham, France.
The company’s Hanau-based GMP facility for advanced pharmaceutical lipids will continue operating. The facility supports clinical and small-scale commercial quantities of pharmaceutical lipids used in drug delivery technologies such as RNA therapeutics.
ProChem is a multi-site contract manufacturer with capabilities across chemical production and analytics. Its services include synthesis, distillation, extraction, drying, mixing, grinding, sieving, packaging, and analytical testing.
The company serves industries including pharmaceuticals, cosmetics, food additives, and specialty chemicals.
Evonik said the transaction supports its broader strategy of focusing on high-growth areas while continuing to serve the pharmaceutical industry with functional excipients, technologies, CDMO services, APIs, intermediates, and cell culture solutions.
KEY QUOTES:
“Refining our focus and aligning our assets enables us to deliver even more strongly in the areas where we create the highest value for our customers.”
Guido Skudlarek, Head of the Health Care Business Line at Evonik
“With this step we are strengthening our position in these highly attractive markets to offer our customers supply security with a broad portfolio across markets.”
Thomas Hermann, Head of the REXIM Product Line at Evonik
“We are gaining state-of-the-art facilities, quality-assured processes, and an excellent industrial infrastructure at the Hanau site. This enables us to significantly expand our service portfolio and offer our customers even more comprehensive, scalable, and regulatory-compliant solutions in the future.”
Jörg Blumhoff, Chief Sales Officer at ProChem Group
